Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder

International Clinical Psychopharmacology
Eric Hollander, Bernardo Dell'Osso

Abstract

We report a case of treatment-resistant obsessive-compulsive disorder (OCD) that was successfully treated with a pharmacological augmentation of topiramate plus paroxetine. The patient, a 45-year-old woman, was on a stable dose of paroxetine (40 mg/day) when she was started on topiramate (up to 150 mg/day). After 9 weeks of this treatment, her clinical condition remarkably improved, as indicated by a significant decrease of the evaluation scales (Yale-Brown Obsessive-Compulsive Scale and Clinical Global Impression Scale). Our case suggests that topiramate might be beneficial in augmentation with selective serotonin reuptake inhibitors in patients with treatment-resistant OCD, although further investigations are warranted to confirm our findings.

References

Nov 1, 1989·Archives of General Psychiatry·W K GoodmanD S Charney
Nov 1, 1989·Archives of General Psychiatry·W K GoodmanD S Charney
Dec 1, 1988·Archives of General Psychiatry·M KarnoM A Burnam
Jan 1, 1998·Transplantation Proceedings·M R First
Jun 23, 2000·Biological Psychiatry·S L McElroyR M Post
Jun 2, 2001·Journal of Clinical Psychopharmacology·J R CalabreseM D Shelton
Feb 13, 2002·The Journal of Clinical Psychiatry·Jeffrey Berlant, Daniel P van Kammen
Jul 18, 2002·Journal of Neurology, Neurosurgery, and Psychiatry·T JochumH Sauer
Jul 24, 2002·The International Journal of Neuropsychopharmacology·Stefano PallantiUNKNOWN International Treatment Refractory OCD Consortium
Aug 20, 2002·Journal of Neurology, Neurosurgery, and Psychiatry·J M S Pearce
Jul 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Alicia Kaplan, Eric Hollander
Mar 2, 2005·Journal of Clinical Psychopharmacology·Marcia Kaplan

❮ Previous
Next ❯

Citations

Oct 23, 2012·Psychopharmacology·Nobuaki EgashiraMichihiro Fujiwara
May 24, 2006·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Donatella Marazziti, Bernardo Dell'Osso
Jan 26, 2012·Clinical Ophthalmology·Mohammad-Ali AbtahiMojtaba Akbari
Nov 18, 2009·British Journal of Clinical Pharmacology·Nasir MirzaMunir Pirmohamed
Oct 26, 2011·Pharmacology, Biochemistry, and Behavior·Ke WuPaul D Arnold
Oct 4, 2011·Pharmacology & Therapeutics·Christopher PittengerKyle Williams
Aug 16, 2008·The Mount Sinai Journal of Medicine, New York·Heather A BerlinEric Hollander
May 17, 2008·CNS Neuroscience & Therapeutics·Richard P Shank, Bruce E Maryanoff
Mar 23, 2007·Expert Opinion on Pharmacotherapy·Leonardo F FontenelleMarcio Versiani
Jan 26, 2010·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Margaret A RichterJames L Kennedy
Dec 1, 2010·Child & Adolescent Psychopharmacology News·Frank P MacMaster, David R Rosenberg
Jan 16, 2010·Journal of Clinical Psychopharmacology·S Evelyn StewartMichael A Jenike
Nov 10, 2017·Current Medicinal Chemistry·Donatella MarazzitiArmando Piccinni
Jul 9, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Leonardo F FontenelleMarcio Versiani
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Sep 17, 2020·Journal of Psychiatric Practice·Vitor DE Mello NettoStefano Pallanti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.